Fluorescence-Based Phenotypic Selection Allows Forward Genetic Screens in Haploid Human Cells by Duncan, Lidia M. et al.
Fluorescence-Based Phenotypic Selection Allows
Forward Genetic Screens in Haploid Human Cells
Lidia M. Duncan






3, Paul J. Lehner
1*
1Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge, United Kingdom, 2The Wellcome Trust Sanger Institute, The Wellcome Trust Genome
Campus, Hinxton, United Kingdom, 3MRC Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Cambridge, United Kingdom
Abstract
The isolation of haploid cell lines has recently allowed the power of forward genetic screens to be applied to mammalian
cells. The interest in applying this powerful genetic approach to a mammalian system is only tempered by the limited utility
of these screens, if confined to lethal phenotypes. Here we expand the scope of these approaches beyond live/dead screens
and show that selection for a cell surface phenotype via fluorescence-activated cell sorting can identify the key molecules in
an intracellular pathway, in this case MHC class I antigen presentation. Non-lethal haploid genetic screens are widely
applicable to identify genes involved in essentially any cellular pathway.
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Introduction
Forwardgeneticanalysis–theconceptofidentifyinggenefunction
from mutants with a discernible phenotype – has a proven track
record of elucidating gene function. However, the difficulty in
generating and recovering bi-allelic mutations in diploid cells is a
major barrier to the application of this approach in the study of
mammalianbiology.Inamajorbreakthrough,threegroupsrecently
circumventedthisproblembypioneeringforwardgeneticscreensin
haploid cells. Carette and colleagues [1] initially demonstrated the
powerofthisapproachbyperformingforwardgeneticscreensinthe
near-haploid human KBM7 chronic myeloid leukemia cell line [2].
By creating a library of knockout KBM7 cells using a gene-trap
retrovirusandscreeningformutantcellsresistanttoarangeoflethal
insults, including bacterial toxins and cytotoxic viruses, they
identified host genes required for toxin or viral killing [1,3,4]. More
recently,twoindependentgroupsderivedhaploidmurineembryonic
stem cells lines and demonstrated the ability to perform forward
geneticscreenstoidentifygenesrequiredforsensitivitytotoxins[5,6].
In all these three examples, cells with mutations in relevant genes
were isolated due to their resistance to a lethal insult. Such lethality
screensarethesimplesttoperformbuthaveinherentlimitations.Few
cellular processes are readily adaptable to a live/dead screen, and
mutationsthatresultinanintermediatephenotypeareunlikelytobe
recovered. For haploid genetic screens to have widespread utility, a
system is required whereby cells with relevant mutations can be
selectedbasedonachangeincellsurfacephenotypeortheexpression
ofagenetically-encodedreporter.Theabilitytoscreenonnon-lethal
phenotypes would greatly expand the scope of these methods such
that they could be used to identify genes involved in essentially any
cell-autonomous process.
Our aim was to test the applicability of this approach and
determine whether cells with relevant mutations could be selected
from a library of mutagenised near-haploid KBM7 cells on the
basis of a change in cell surface phenotype. We chose to probe the
cell surface expression of major histocompatibility complex class I
(MHC-I) molecules, since the MHC-I antigen presentation
pathway is well-characterized and utilizes a number of discrete
components which function in a coordinated fashion to promote
trafficking of peptide-loaded MHC-I molecules to the cell surface
[7]. Newly-synthesized MHC-I heavy chains are co-translationally
inserted into the endoplasmic reticulum (ER) where they
heterodimerise with beta-2-microglobulin (b2m). MHC-I mole-
cules then associate with the TAP peptide transporter (TAP1/2)
via tapasin, a dedicated MHC-I chaperone which allows MHC-I
access to TAP-delivered peptides generated from proteasome-
mediated degradation of cytosolic proteins [7]. The successful
loading of MHC-I molecules with peptide allows their release from
the peptide loading complex and exit from the ER to the cell
surface, where they present peptides to cytotoxic T lymphocytes
(CTL). Here we show that KBM7 cells unable to present MHC-I
molecules at the cell surface can be selected from a mutagenized
library by fluorescence-activated cell sorting (FACS), and use this
approach to isolate mutant clones deficient for components of the
MHC-I antigen presentation pathway.
Results
A Haploid Genetic Screen to Identify Genes Required for
Cell Surface MHC-I Expression
Near-haploid KBM7 cells express high cell surface MHC-I
and HLA typing showed them to be HLA-A2, HLA-B60 and
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retrovirus [1] to create a library of knockout cells, which were
then selected by fluorescence-activated cell sorting (FACS) for
the very small population of cells (,0.02%) expressing low cell
surface MHC-I (Fig. 1A). Two sequential sorts were required,
with each sort enriching the selected population by at least two
orders of magnitude. Following the first sort a small population
of MHC-I
low cells was visualized (,8%), which was further
enriched to near purity during the second sort (Fig. 1B). Three
separate screens were performed using different anti-MHC-I
primary antibodies: w6/32, which recognizes total MHC-I,
BB7.2, which is specific for HLA-A2, and 4E, which recognizes
the HLA-B molecule. In each case, we selected for cells
displaying reduced cell surface MHC-I. To identify the
disrupted genes responsible for the defect in MHC-I expression,
the retroviral integration sites in all sets of selected cells were
amplified using splinkerette-PCR and sequenced using 454
pyrosequencing [8,9]. Together this analysis revealed retroviral
insertions in four genes known to be involved in the MHC-I
antigen presentation pathway: 9 independent retroviral integra-
tions were found in the gene encoding b2m, 8 in tapasin
(TAPBP), 2 in TAP2 and 1 in the HLA-A2 gene itself (Fig. 1C).
Overall, the identification of multiple known genes in the
pathway demonstrates the power of this approach for interro-
gating the genetic basis of cellular processes.
Generating Mutant Clones Deficient for Components of
the MHC-I Antigen Presentation Pathway
A major advantage of this technique is that genetically-deficient
knockout human cells are generated as part of the screen, which
therefore provides an invaluable resource to allow further
functional characterization of the disrupted gene. To isolate
knockout clones for the four genes involved in the MHC-I
pathway, we plated single cells from the FACS-selected MHC-I
low
populations into 96-well plates and identified the gene-trap
insertion site in the resulting clones by PCR (Fig. 2A). Cells
deficient in each of the four genes were recovered. The lack of
expression of the disrupted genes was readily confirmed by RT-
PCR (Fig. 2B), and we verified a functional knockout in each case
by flow cytometry (Fig. 2C). Knockout of b2m abolished total cell
surface MHC-I expression, while the knockout of HLA-A2
prevented only HLA-A2 surface expression, but left HLA-B60
and total MHC-I unaffected. Cells deficient in TAP2 and tapasin
showed decreased surface MHC-I, with a more marked effect on
HLA-B60 than HLA-A2, consistent with reports that the HLA-B
heavy chain is more TAP-dependent since HLA-A2 can acquire
TAP-independent, signal sequence-derived peptides [10,11].
Discussion
The enormous potential of forward genetic screens in cultured
haploid mammalian cells is only tempered by their restricted use to
Figure 1. A haploid genetic screen to identify genes required for cell surface expression of MHC-I molecules. A. Schematic of the
screen. B. Selecting MHC-I
low cells by FACS. Mutagenised KBM7 cells were labeled for surface MHC-I and those cells defective for MHC-I presentation
enriched by two sequential rounds of FACS. The FACS plots correspond to the stages of the screen outlined above them in A. C. The genetic screen
identifies multiple genes known to be involved in the MHC-I antigen presentation pathway. Important genes within the MHC-I antigen presentation
pathway are targeted by multiple independent retroviral integrations (red triangles).
doi:10.1371/journal.pone.0039651.g001
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phenotypes by FACS allows haploid genetic screens to be
performed in human KBM7 cells leading to the identification of
key components of an intracellular pathway. Fluorescent labeling
and subsequent sorting for MHC-I
low cells among a library of
mutagenised KBM7 cells led to the successful isolation of knockout
KBM7 clones deficient in four components of the MHC-I antigen
presentation pathway. This powerful approach can therefore be
used to identify multiple components of an intracellular pathway.
Furthermore, the iterative enrichment of cells expressing the
desired phenotype by FACS, as opposed to screens based on live/
dead phenotypes, has the additional advantage of identifying
mutant cells with intermediate phenotypes (for example, as with
the TAP2 and tapasin knockout cells) which are less likely to be
identified in live/dead screens.
The efficient assembly of peptide loaded MHC-I molecules
requires both MHC-I dedicated components (TAP, tapasin, the
class I heavy chain and b2m) as well as more general cellular
chaperones (calnexin, calreticulin and ERp57). While the majority
of MHC-I dedicated components were identified in our screen, no
mutations were found in genes encoding the more generalized
cellular chaperones. Either the functions of these chaperones are
redundant, or a growth disadvantage in cells deficient in these
genes prevented clones from surviving the selection process.
Another solution to broaden the utility of haploid genetic
screens is to convert an otherwise non-toxic screening agent into a
lethal one to permit a live/dead screen. By attaching the catalytic
subunit of diphtheria toxin to cholera toxin, which by itself is not
lethal to KBM7 cells, Guimaraes and colleagues [12] identified
new host genes required for cholera toxin intoxication. This
approach is limited, however, as mutations will always be found in
genes required for sensitivity to the toxic agent. Furthermore,
mutations that confer only partial resistance are unlikely to be
recovered. In contrast, the selection of mutant cells by FACS
allows screens to be performed on a wide range of non-lethal
phenotypes, and has the potential to identify mutations with an
intermediate effect. This was the case in our MHC-I screens, as we
successfully recovered cells deficient in TAP2 and tapasin, loss of
which results in a partial rather than a total loss of cell surface
MHC-I expression.
Figure 2. Isolation of knockout clones deficient for components of the MHC-I antigen presentation pathway. A. Identifying knockout
clones by PCR. A schematic representation of the b2m, tapasin and TAP2 knockout clones identified by PCR from 96 single cell clones from the HLA-
B
low selected population. Screening a relatively low number of single cell clones is sufficient to identify knockout cells representing the relevant
target genes found in a screen. B. The gene-trap insertions result in a loss of gene expression. The knockout clones were analyzed for HLA-A2, b2m,
tapasin and TAP2 expression by RT-PCR. C. Knockout of genes involved in the MHC-I pathway impairs cell surface expression of MHC-I molecules. The
b2m, HLA-A2, tapasin and TAP2 knockout clones were labeled for the indicated proteins and analyzed by flow cytometry.
doi:10.1371/journal.pone.0039651.g002
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genetic screens to be performed in mutagenised haploid human
KBM7 cells by enriching for cells of the desired phenotype.
Although we have used this technique to select cells on the basis of
a change in cell surface phenotype, this method is equally
applicable to the selection of cells based on altered expression of a
genetically-encoded fluorescent reporter. The ability to perform
forward genetic screens in near-haploid KBM7 cells on non-lethal
phenotypes opens up this technology for interrogating the genetic
basis of a wide range of cellular processes.
Materials and Methods
Cell Culture
KBM7 cells [2] and HEK 293ET cells were maintained in
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented
with 10% fetal calf serum and 1% penicillin/streptomycin.
Antibodies
The mAb W6/32 recognizes conformational MHC-I [13]; mAb
BB7.2 (recognizes conformational HLA-A2) and mAb 4E (recog-
nizes conformational HLA-B) were generous gifts from P.
Cresswell. The Cy5-conjugated goat anti-mouse IgG secondary
antibody was obtained from Jackson ImmunoResearch.
Gene-trap Mutagenesis
The gene-trap vectors pGT0-GFP, pGT+1-GFP and pGT+2-
GFP were a generous gift from T. Brummelkamp [1]. The
bidirectional SV40 polyadenylation signal was replaced with a
unidirectional one amplified as a BamHI-MluI fragment from the
plasmid Flx800.15, to create pGT0-GFP-pA, pGT+1-GFP-pA
and pGT+2-GFP-pA. Mutagenised KBM7 libraries were gener-
ated using a mixture of all three vectors.
Retrovirus was produced in HEK 293ET cells. HEK 293ET
cells at greater than 90% confluency in a 6-well plate were
transfected with 4 mg total DNA using Lipofectamine 2000
(Invitrogen). The gene-trap vectors plus the packaging plasmids
pMD.GagPol and pMD.VSVG were mixed in a ratio of 10:7:3 in
250 ml OptiMEM (Invitrogen), mixed with 10 ml transfection
reagent diluted in 250 ml OptiMEM, incubated for 20 min at
room temperature and added dropwise to the cells growing in
media without antibiotics. The virus-containing supernatant was
harvested from 48 h post-transfection, filtered through a 0.45 mm
filter, and applied directly to 1.5610
6 KBM7 cells in a 24-well
plate in the presence of 10 mg/ml hexadimethrine bromide
(PolybreneH, Sigma-Aldrich). The cells were then spun at




5 cells were washed with PBS, spun down
(1600 rpm, 5 min, 4uC) and resuspended in 50 ml PBS. Primary
antibody was then applied for 15 min at 4uC. The cells were then
washed again with PBS, spun down, resuspended in 50 ml PBS
and stained with a flurochrome-conjugated secondary antibody for
15 min at 4uC in the dark. Following a final wash step, the cells




7 cells mutagenised cells were labeled with primary
antibody for 15 min at 4uC in a total volume of 1 ml, washed with
PBS, and then labeled with a Cy5-conjugated anti-mouse IgG
secondary antibody in the same way. Sorting was carried out on
an Influx cell sorter (BD Biosciences).
Mapping of Retroviral Integration Sites and 454
Pyrosequencing
We employed a splinkerette PCR-based method to identify
retroviral insertion sites, broadly as described by Koudijs and
colleagues [9]. Briefly, genomic DNA was extracted from 1 million
KBM7 cells (Gentra Puregene kit) and sheared by sonication
(BioruptorH, Diagenode) to an average fragment size of ,400 bp.
DNA fragment ends were blunted with T4 DNA polymerase
(NEB), phosphorylated with T4 polynucleotide kinase (NEB) and
ligated with annealed splinkerette adaptors (59- GTTCCCATGG-
TACTACTCATATAATACGACTCACTATAGG-39 and 59-
CCTATAGTGAGTCGTATTATAATTTTTTTTT-
CAAAAAAA-39). Following digestion with BpmI (NEB), two
rounds of PCR were carried out using one set of primers binding
to the 59LTR of the retroviral gene-trap vector and another set of
primers binding to the splinkerette adaptor. For 454 pyrosequenc-
ing, the second round virus-end PCR primer included GS FLX
454 primer A plus a 10 bp barcode and the second round adaptor-
end primer contained primer B. Primer sequences are detailed in
Table S1. Multiplexing was achieved by amplifying samples from
the different screens with unique barcode sequences; the DNA
concentration of each sample following PCR amplification was
quantified using a PicoGreen assay (Invitrogen) and mixed evenly.
Following a column clean-up step (Qiagen PCR purification kit),
the total library of PCR products was sequenced using the Lib-L
emPCR kit (Roche) using one-quarter of a picotitre plate on a 454
GS FLX Titanium sequencing instrument (Roche). Processing of
454 reads was achieved using the Galaxy FASTX toolkit [14].
Reads were sorted by barcode, trimmed of viral and adaptor
sequences, aligned to the human genome (hg19) using LastZ and
visualized in IGV [15].
Identification of Mutant Clones
FACS-selected MHC-I
low mutant cells were plated into
individual wells of a 96-well plate. Three weeks later genomic
DNA was extracted from the resulting clones and the site of the
gene-trap insertion identified by PCR, using one primer (GFP_R)
binding to the GFP in the gene-trap virus and the second primer
binding at an appropriate distance from the insertion site within
the HLA-A2, B2M, tapasin and TAP2 genes (Table S1).
RT-PCR
Total RNA was extracted from KBM7 cells using the RNeasy
Plus Mini Kit (Qiagen), and converted into cDNA by the addition
of reverse transcriptase and an oligodT primer. A PCR reaction
was then carried out using two primers binding within the mRNAs
of the target genes designed to produce a ,200 bp amplicon
(Table S1). Products were visualized on a 2% agarose gel.
Supporting Information
Table S1 Primer sequences.
(DOC)
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